Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marcela V Maus"'
Autor:
Matthew J. Frigault, Michael R. Bishop, Jacalyn Rosenblatt, Elizabeth K. O’Donnell, Noopur Raje, Daniella Cook, Andrew J. Yee, Emma Logan, David E. Avigan, Andrzej Jakubowiak, Kit Shaw, Heather Daley, Sarah Nikiforow, Faith Griffin, Christine Cornwell, Angela Shen, Christopher Heery, Marcela V. Maus
Publikováno v:
Blood Advances. 7:768-777
Relapsed and refractory multiple myeloma (RRMM) is a plasma cell neoplasm defined by progressively refractory disease necessitating chronic and increasingly intensive therapy. Despite recent advances, limited treatment options exist for RRMM. This si
Autor:
Nikhil C. Munshi, Christopher J. Gibson, Caron A. Jacobson, Peter Miller, Max Jan, Mark B. Leick, Geoffrey Fell, Benjamin L. Ebert, Marcela V. Maus, Elliott J. Brea, Yu-Tzu Tai, Satyen H. Gohil, Donna Neuberg, Catherine J. Wu, Adam S. Sperling
Publikováno v:
Blood Adv
Chimeric antigen receptor (CAR) T-cells have emerged as an efficacious modality in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Clonal hematopoiesis of indeterminate potential (CHIP), a state in which mutations in hematopoietic
Autor:
Saar Gill, Vanessa Vides, Noelle V. Frey, Elizabeth O. Hexner, Susan Metzger, Megan O'Brien, Wei-Ting Hwang, Jennifer L. Brogdon, Megan M. Davis, Joseph A. Fraietta, Avery L. Gaymon, Whitney L. Gladney, Simon F. Lacey, Anne Lamontagne, Anthony R. Mato, Marcela V. Maus, J. Joseph Melenhorst, Edward Pequignot, Marco Ruella, Maksim Shestov, John C. Byrd, Stephen J. Schuster, Donald L. Siegel, Bruce L. Levine, Carl H. June, David L. Porter
Publikováno v:
Blood advances. 6(21)
In chronic lymphocytic leukemia (CLL) patients who achieve a complete remission (CR) to anti-CD19 chimeric antigen receptor T cells (CART-19), remissions are remarkably durable. Preclinical data suggesting synergy between CART-19 and the Bruton’s t
Autor:
Amanda A. Bouffard, Kenneth C. Anderson, Lauren S. Riley, Bryan D. Choi, Ana P. Castano, Rebecca C. Larson, Wolfgang W. A. Schamel, Yu-Tzu Tai, Matthew J. Frigault, Andrea Schmidts, Marcela V. Maus, Sean G Mackay, Maria Ormhøj, Maria L. Cabral, Rubí M.-H. Velasco Cárdenas, Jing Zhou, Irene Scarfò, Kathleen Gallagher, Angela C. Boroughs, Allison Taylor
Publikováno v:
Schmidts, A, Ormhøj, M, Choi, B D, Taylor, A O, Bouffard, A A, Scarfò, I, Larson, R C, Frigault, M J, Gallagher, K, Castano, A P, Riley, L S, Cabral, M L, Boroughs, A C, Velasco Cárdenas, R M H, Schamel, W, Zhou, J, Mackay, S, Tai, Y T, Anderson, K C & Maus, M V 2019, ' Rational design of a trimeric April-based CAR-binding domain enables efficient targeting of multiple myeloma ', Blood Advances, vol. 3, no. 21, pp. 3248-3260 . https://doi.org/10.1182/bloodadvances.2019000703
Chimeric antigen receptor (CAR) T cells (CARTs) have shown tremendous potential for the treatment of certain B-cell malignancies, including patients with relapsed/refractory multiple myeloma (MM). Targeting the B-cell maturation antigen (BCMA) has pr
Autor:
J. Erika Haydu, Jenny S. Maron, Robert A. Redd, Kathleen M. E. Gallagher, Stephanie Fischinger, Jeffrey A. Barnes, Ephraim P. Hochberg, P. Connor Johnson, R. W. Takvorian, Katelin Katsis, Daneal Portman, Jade Ruiters, Sidney Sechio, Mary Devlin, Connor Regan, Kimberly G. Blumenthal, Aleena Banerji, Allen D. Judd, Krista J. Scorsune, Brianne M. McGree, Maryanne M. Sherburne, Julia M. Lynch, James I. Weitzman, Matthew Lei, Camille N. Kotton, Anand S. Dighe, Marcela V. Maus, Galit Alter, Jeremy S. Abramson, Jacob D. Soumerai
Publikováno v:
Blood Advances
Chronic lymphocytic leukemia (CLL), the most common leukemia worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a portion of vaccinated CLL patients develop severe acute respiratory syndrome coronavirus 2 (SARS-
Autor:
Marcela V. Maus, Caron A. Jacobson
Publikováno v:
Blood Adv
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has transformed the natural history of relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell non-Hodgkin lymphoma. Based on these results, CD19 CAR T cells have